Cargando…

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

SIMPLE SUMMARY: Predictive and prognostic factors are necessary to evaluate the future of women with early breast cancer. Inflammatory blood markers such as neutrophil to lymphocytes ratio and platelet to lymphocytes ratio have been reported to be a predictive factor for pathological complete respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corbeau, Ileana, Thezenas, Simon, Maran-Gonzalez, Aurelie, Colombo, Pierre-Emmanuel, Jacot, William, Guiu, Severine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564656/ https://www.ncbi.nlm.nih.gov/pubmed/32962003 http://dx.doi.org/10.3390/cancers12092666

Ejemplares similares

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
por: Corbeau, Iléana, et al.
Publicado: (2020)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study
por: Viala, Marie, et al.
Publicado: (2018)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
por: Viala, Marie, et al.
Publicado: (2021)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Clinical and Prognostic Significance of Pathological and Inflammatory Markers in Mucinous Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy and Curative Surgery
por: Zhao, Jian, et al.
Publicado: (2017)

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases
por: Braccini, Antoine-Laurent, et al.
Publicado: (2013)

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy
por: Zheng, Chen, et al.
Publicado: (2023)

The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy
por: Yu, Hong, et al.
Publicado: (2022)

Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
por: Pataer, Apar, et al.
Publicado: (2022)

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer
por: El Demery, Mounira, et al.
Publicado: (2014)

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study
por: Fabbro, Michel, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
por: Yang, Jing, et al.
Publicado: (2018)

Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma
por: Willmer, Denise, et al.
Publicado: (2021)

Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016)

Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Truffi, Marta, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
por: Li, Yang, et al.
Publicado: (2018)

Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis
por: Xue, Ling Bo, et al.
Publicado: (2019)

In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

Prognostic Value of Systemic Inflammatory Response Markers in Patients Undergoing Neoadjuvant Chemotherapy and Gastrectomy for Advanced Gastric Cancer in the Eastern European Population
por: Pikuła, Agnieszka, et al.
Publicado: (2022)

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy
por: Herrero-Vicent, C, et al.
Publicado: (2016)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
por: Ko, Eun Sook, et al.
Publicado: (2015)

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2016)

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Xu, Yuhao, et al.
Publicado: (2022)

Implanted markers prior to neoadjuvant chemotherapy: preliminary report
por: Allan for the Dartford Breast Care Team, DM
Publicado: (2000)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy
por: Gensthaler, Lisa, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease
por: Li, Jing, et al.
Publicado: (2017)

Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
por: Zhou, Qiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gbugg8j98pk0s50g0g41862fu0